

Mozambique Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Mozambique				
2. Grant number: 1819-MOZ-18c-X/ 17-MOZ-18d-X / 17-MOZ-35b-Y / 18-MOZ-08I-Y				
3. Date of Decision Letter: 10 April 2018				
4. Date of the Partnership Framework Agreement: 06 December 2013				
5. Programme title: NVS, Routine Measles-Rubella Catch-up Campaign				
6. Vaccine type: Measles rubella				
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED				
8. Programme duration¹: 2017-2019				
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)				
	2017	2018	2019	Total ²
Programme Budget Routine (US\$)		721,500	604,000	1,325,500
Programme Budget Campaign (US\$)	9,499,000			9,499,000
Total (US\$)	9,499,000	721,500	604,000	10,824,500
10. Vaccine introduction grant (in US\$): US\$933,198				
11. Indicative annual amounts:				
Type of supplies to be purchased with Gavi funds in each year (Routine)		2018		
Number of Measles-Rubella vaccines doses		1,148,600		
Annual Amounts (US\$)		US\$721,500		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

Type of supplies to be purchased with Gavi funds in each year (Campaign)	2017
Number of Measles-Rubella vaccines doses	15,125,700
Annual Amounts (US\$)	US\$9,499,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns:

	2017
Grant amount (US\$)	US\$7,935,500

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Supplementary Immunisation Activity (SIA) technical report	Within 3 months of end of campaign
Post campaign coverage survey report	As soon as available

17. Financial clarifications: Not applicable

18. Other conditions:

As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
10 April 2018